Immage Competitors
| IMMG Stock | USD 0.0001 0.00 0.00% |
Immage Biotherapeutics vs CTR Investments Correlation
Moving against Immage Stock
The current Return On Tangible Assets is estimated to decrease to -0.86. The Immage Biotherapeutics' current Return On Capital Employed is estimated to increase to -1.26. At this time, Immage Biotherapeutics' Other Current Assets are most likely to increase significantly in the upcoming years. The Immage Biotherapeutics' current Total Current Assets is estimated to increase to about 247.6 K, while Return On Tangible Assets are projected to decrease to (0.86).Immage Biotherapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Immage Biotherapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Immage and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Immage Biotherapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Immage Stock performing well and Immage Biotherapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Immage Biotherapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BITCF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| TLGN | 4.41 | 2.26 | 0.00 | 139.67 | 0.00 | 0.00 | 100.00 | |||
| CHFI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| RNBI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| EURI | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| BLPFF | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| WNCG | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| AXTG | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| XYNH | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| CIVX | 8.49 | 1.01 | 0.00 | (0.26) | 0.00 | 33.33 | 150.00 |
Cross Equities Net Income Analysis
Compare Immage Biotherapeutics and related stocks such as First BITCoin Capital, Totally Green, and China Finance Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BITCF | (46.8 K) | (46.8 K) | (46.8 K) | (46.8 K) | (46.8 K) | (47.3 K) | 3.8 K | (2.3 M) | (393.4 K) | (393.4 K) | (393.4 K) | (393.4 K) | (393.4 K) | (393.4 K) | (393.4 K) | (354.1 K) | (371.8 K) |
| CHFI | (2.7 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (18.4 M) | (16.5 M) | (15.7 M) |
| RNBI | (4.8 K) | (46.4 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (243.9 K) | (219.5 K) | (208.5 K) |
| EURI | (23 K) | (23 K) | (23 K) | (112 K) | (256.8 K) | (386.7 K) | (386.7 K) | (386.7 K) | (386.7 K) | (386.7 K) | (386.7 K) | (386.7 K) | (386.7 K) | (386.7 K) | (386.7 K) | (348 K) | (330.6 K) |
| WNCG | (1.1 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.6 M) | (1.7 M) |
| XYNH | (113.2 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (456.8 K) | (411.1 K) | (431.7 K) |
Immage Biotherapeutics and related stocks such as First BITCoin Capital, Totally Green, and China Finance Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Immage Biotherapeutics financial statement analysis. It represents the amount of money remaining after all of Immage Biotherapeutics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Immage Biotherapeutics Competitive Analysis
The better you understand Immage Biotherapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Immage Biotherapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Immage Biotherapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Immage Biotherapeutics Competition Performance Charts
Five steps to successful analysis of Immage Biotherapeutics Competition
Immage Biotherapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Immage Biotherapeutics in relation to its competition. Immage Biotherapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Immage Biotherapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Immage Biotherapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Immage Biotherapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Immage Biotherapeutics position
In addition to having Immage Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Energy Thematic Idea Now
Alternative Energy
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Immage Biotherapeutics Correlation with its peers. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Can Biotechnology industry sustain growth momentum? Does Immage have expansion opportunities? Factors like these will boost the valuation of Immage Biotherapeutics. Market participants price Immage higher when confident in its future expansion prospects. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Immage Biotherapeutics demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Immage Biotherapeutics's market price often diverges from its book value, the accounting figure shown on Immage's balance sheet. Smart investors calculate Immage Biotherapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since Immage Biotherapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Immage Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immage Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immage Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.